Idexx Laboratories, Inc.
IDXX
Market Cap$39.68B
Close$
Earnings Call Q4 2023
February 5, 2024 - AI Summary
IDEXX Laboratories reported strong fourth quarter and full year 2023 results, with revenues increasing by 8% organically in Q4 and 9% for the full year.
CAG Diagnostic recurring revenue grew by 10% organically in Q4, driven by gains in both the US (9%) and international regions (12%).
The company achieved solid organic growth across major testing modalities, with VetLab consumable revenues increasing by 13% organically in Q4.
Exclusive for Stockcircle Pro members
Sign up
$155.84
68.5% downside
Current Fair Value
68.5% downsideOvervalued by 68.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $39.68 Billion |
|---|---|
| Enterprise Value | $40.18 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $10.06 |
| Beta | 1.41 |
| Outstanding Shares | 83,054,119 |
| Avg 30 Day Volume | 400,200 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 46.96 |
|---|---|
| PEG | 362.4 |
| Price to Sales | 11.23 |
| Price to Book Ratio | 29.07 |
| Enterprise Value to Revenue | 10.97 |
| Enterprise Value to EBIT | 36.62 |
| Enterprise Value to Net Income | 47 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
ESG Score
No data
About Idexx Laboratories, Inc.
CEO: Jonathan Jay Mazelsky